Type 1 diabetes treatment is undergoing its most dramatic transformation in a century. For the first time, disease-modifying therapies like teplizumab are delaying clinical onset by targeting the autoimmune process itself, while stem-cell–derived β-cell replacement therapies are showing proof-of-concept for restoring natural insulin production. At the same time, next-generation insulins—ultrarapid, once-weekly, and even glucose-responsive—are converging with automated insulin delivery systems to bring care closer to physiological glucose control than ever before.
Keep Reading
Add A Comment